Efficacy and safety of bivalos therapy for postmenopausal osteoporosis. results of russian multicenter trial
- 作者: Rozhinskaia L1, Arapova S1, Dzeranova L1, Molitvoslovova N1, Marova E1, Il'in A1, Benevolenskaia L2, Nikitinskaia O2, Korotkova T2, Toroptsova N1, Smirnov A1, Demin N2, Rodionova S3, Buklemeshev I.3, Shumskiĭ A3
-
隶属关系:
- ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
- ГУ Институт ревматологии РАМН, Москва
- ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва
- 期: 卷 80, 编号 5 (2008)
- 页面: 47-52
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30170
- ID: 30170
如何引用文章
全文:
详细
作者简介
L Rozhinskaia
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
S Arapova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
L Dzeranova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
N Molitvoslovova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
E Marova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
A Il'in
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
L Benevolenskaia
ГУ Институт ревматологии РАМН, Москва
O Nikitinskaia
ГУ Институт ревматологии РАМН, Москва
T Korotkova
ГУ Институт ревматологии РАМН, Москва
N Toroptsova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
A Smirnov
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
N Demin
ГУ Институт ревматологии РАМН, Москва
S Rodionova
ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва
Iu Buklemeshev
ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва
A Shumskiĭ
ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва
参考
- Seeman Е. Pathogenesis of bone fragility in women and men. Lancet. 2002; 359: 1841-1850.
- Black D. M., Cummings S. R., Karpf D. B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
- Boivin G. Y., Chavassieux P. M., Santora А. C. et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. J. Bone 2000; 27: 687-694.
- Ettinger В., Black D. M., Mitlak В. H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treatment with raloxifene: results from a 3-year randomized clinical trial. J. A. M. A. 1999; 282: 637-645.
- Arnaud C. D., Zanchetta J. R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001; 344: 1434-1441.
- Chavassieux P. M., Arlot M. E., Reda C. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 1997; 100: 1475-1480.
- Meunier P. J., Slosman D. O., Delmas P. D. et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 2002; 87: 2060-2066.
- Reginster J. Y., Meunier P. J. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. J. Osteoporos. Int. 2003; 14 (suppl. 3): S56-S65.
- Meunier P. J., Roux C., Seeman E. el al. The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004; 350: 459-468.
- Reginster J. Y., Seeman E., De Vernejoul M. C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 2005; 90: 2816-2822.
- Bruyere O., Roux C., Cannata J. B. et al. Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelate. J. Osteoporos. Int. 2006; 17 (suppl. 1): s8.
- Bruyere O., Delmas P. D., Devogelaer J.-P. et al. Relations between increase in femoral neck bone mineral density and decrease in hip fracture incidence during treatment with strontium ranelate. J. Osteoporos. Int. 2006; 17 (suppl. 1): s96.
- Meunier P. J., Arlot M. E., Roux J. P. et al. How to rebalance bone turnover in favor of formation. J. Osteoporos. Int. 2006; 17 (suppl. 1): si 14.
- Buehler J., Chappuis P., Saffar J. L. et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). J. Bone 2001; 29: 176-179.
- Marie P. J. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. J. Osteoporos. Int. 2003; 14 (suppl. 3): S9-S12.
- Roux С., Reginster J. Y., Fechtenbaum J. et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Mineral Res. 2006. Online published January, 22.
- Reginster J. Y., Sarlet N., Lejeune E., Leonori L. Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. J. Curr. Osteoporos. Rep. 2005; 1: 30-34.
- Neer R. M., Arnaud С. D., Zanchetta J. R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001; 344: 1434-1441.
- Marquis P. et al. J. Osteoporos. Int. 2005; 16 (3): S54, abstr. P223.